U.S. Gas Utilities Stock News

NYSE:IFF
NYSE:IFFChemicals

International Flavors & Fragrances (IFF) Is Up 10.4% After 2026 Guidance And Food Ingredients Sale Plan

In February 2026, International Flavors & Fragrances Inc. reported mixed fourth-quarter 2025 results, with sales of US$2,589 million down from US$2,771 million a year earlier, a swing to full-year 2025 net loss of US$374 million, and issued 2026 sales guidance of US$10.50–US$10.80 billion alongside adjusted EBITDA guidance of US$2.05–US$2.15 billion. At the same time, IFF accelerated its portfolio reshaping by launching a formal sale process for its Food Ingredients business and outlining a...
NasdaqGM:OCUL
NasdaqGM:OCULPharmaceuticals

Ocular Therapeutix (OCUL) Is Down 5.8% After AXPAXLI Phase 3 Update And New Share Registration – What's Changed

Ocular Therapeutix reported fourth-quarter 2025 revenue of US$13.25 million and a net loss of US$64.65 million, and filed an US$8.29 million shelf registration for 974,000 common shares tied to its employee stock plans. The company also recently hosted a webcast to share topline Phase 3 SOL-1 data for its investigational AXPAXLI therapy in wet age-related macular degeneration, a program that could materially influence its long-term pipeline value and competitive positioning in retinal...
NYSE:ATO
NYSE:ATOGas Utilities

Does Atmos Energy’s Governance Overhaul and Share Expansion Reshape the Bull Case for ATO?

In early February 2026, Atmos Energy shareholders approved extensive amendments to the company’s charters and bylaws, including lifting authorized common shares to 400 million and updating rules on director elections, officer liability, indemnification, meeting procedures, and legal forums. These governance changes, together with the board’s alignment on modernized bylaws, give Atmos Energy greater flexibility for future capital raising and corporate actions while tightening legal and...
NYSE:DRD
NYSE:DRDMetals and Mining

Is DRDGOLD (NYSE:DRD) Still Attractively Priced After Its Multi‑Year Share Price Surge

If you are wondering whether DRDGOLD's share price still reflects fair value after its recent run, this article walks through the key valuation checks to help you frame that question clearly. The stock last closed at US$35.65, with a 1.6% return over 7 days, a 1.6% decline over 30 days and returns of 17.6% year to date, 251.3% over 1 year, 412.2% over 3 years and 327.9% over 5 years. Recent coverage has focused on DRDGOLD's share price performance and how investors are reacting to changes in...
NasdaqGS:DUOL
NasdaqGS:DUOLConsumer Services

Is Duolingo (DUOL) Now A Potential Opportunity After A 74% One-Year Share Price Slide?

If you are wondering whether Duolingo is starting to look attractive or still priced for perfection, the recent share price moves give you a lot to think about. The stock closed at US$112.57, with returns of a 5.3% decline over 7 days, a 25.0% decline over 30 days, a 36.2% decline year to date, and a 74.0% decline over the past year, even though the 3 year return sits at 23.2%. Recent coverage has focused on how Duolingo fits into the broader shift toward app based learning and subscription...
NYSE:T
NYSE:TTelecom

Assessing AT&T (T) Valuation After Expanded AWS And Satellite Connectivity Alliance

AT&T (T) is back in focus after expanding its work with Amazon Web Services and Amazon Leo to modernize connectivity infrastructure, migrate key workloads to AWS Outposts, and extend broadband reach using satellite supported solutions. See our latest analysis for AT&T. For context, AT&T’s share price sits at US$28.69, with a 30 day share price return of 22.14% and a 16.82% year to date share price return. Its 5 year total shareholder return of 74.86% reflects performance over a longer horizon...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

A Look At Intellia Therapeutics (NTLA) Valuation After FDA Lifts MAGNITUDE-2 Clinical Hold

The FDA’s decision to lift the clinical hold on Intellia Therapeutics (NTLA) MAGNITUDE-2 study, following protocol changes and safety measures, brings renewed focus to how this gene editing stock may fit into a portfolio. See our latest analysis for Intellia Therapeutics. The FDA news arrives after a mixed stretch for the stock, with a 90 day share price return of 40.14% and a 1 year total shareholder return of 10.93%, set against a 3 year total shareholder return decline of 70.60%. If the...
NYSE:SARO
NYSE:SAROAerospace & Defense

A Look At StandardAero (SARO) Valuation After First CFM LEAP Engine Restoration Milestone

StandardAero (SARO) has completed and delivered its first CFM LEAP engine performance restoration shop visit at its San Antonio facility. This marks a milestone that broadens its LEAP aftermarket offering for a growing global customer base. See our latest analysis for StandardAero. At a share price of $30.57, StandardAero has a 90 day share price return of 24.83% and a 1 year total shareholder return of 15.01%, suggesting recent momentum has strengthened after some near term softness. If this...
NYSE:GEF
NYSE:GEFPackaging

Is It Too Late To Consider Greif (GEF) After Its Strong Multi‑Year Share Price Run?

If you are wondering whether Greif is still reasonably priced after its recent run, you are not alone. This article will focus squarely on what you might be paying for each dollar of the business. The stock last closed at US$76.82, with returns of 3.5% over 7 days, 6.8% over 30 days, 12.2% year to date, 30.2% over 1 year, 18.4% over 3 years and 90.6% over 5 years. This naturally raises questions about how much value is already reflected in the price. Recent coverage of Greif has highlighted...
NasdaqGS:CGNX
NasdaqGS:CGNXElectronic

Cognex Returns To Profitable Growth As AI Products Reshape Business

Cognex (NasdaqGS:CGNX) reported Q4 2025 results that marked a return to profitable growth. Management highlighted an operational turnaround helped by portfolio optimization and cost actions. The quarter included launches of new AI-powered machine vision products and strong new customer intake. Cognex, trading at $58.79, is back in focus after Q4 2025 results showed a shift to profitable growth supported by operational changes. The stock has been strong recently, up 34.5% over the past week,...
NYSE:STZ
NYSE:STZBeverage

Constellation Brands CEO Shift Tests Premium Growth And Capital Allocation Plans

Constellation Brands (NYSE:STZ) has appointed Nicholas Fink as its new CEO, succeeding Bill Newlands. Newlands will remain with the company in an advisory capacity during the leadership transition. Fink previously held senior roles at Fortune Brands Innovations and Suntory Global Spirits. Constellation Brands, the owner of a broad portfolio of beer, wine and spirits labels, operates in a highly competitive consumer beverages market where brand strength and distribution relationships are...
NYSE:AXP
NYSE:AXPConsumer Finance

Assessing American Express (AXP) Valuation After Recent Share Price Weakness

American Express stock snapshot American Express (AXP) has drawn investor attention after a period of mixed recent returns, with the share price around $337.50 and one year total return close to 9.7%. See our latest analysis for American Express. Recent trading has been softer, with a 1-day share price return of a 1.6% decline, a 7-day share price return of a 6.2% decline, and a 30-day share price return of a 7.5% decline. The 1-year total shareholder return of 9.7% and 5-year total...
NYSE:RDN
NYSE:RDNDiversified Financial

Is It Time To Reassess Radian Group (RDN) After Strong Multi‑Year Share Price Gains

If you are wondering whether Radian Group at around US$32.82 is offering good value or not, this article is going to focus squarely on what the current price might mean for long term investors. The stock is roughly flat over the last 7 days at 0.2%, slightly lower over the past month with a 0.9% decline, and shows longer term returns of 3.2% over 1 year, 60.7% over 3 years, and 88.6% over 5 years. Recent coverage around Radian Group has mainly centered on its position in the US mortgage...
NYSE:WPC
NYSE:WPCREITs

Assessing W. P. Carey (WPC) Valuation After Q4 Beat, 2026 Guidance And €1b Notes Offering

W. P. Carey (WPC) is back in focus after a packed fourth quarter, with FFO and revenue above expectations, fresh 2026 guidance, a dividend increase, heavy portfolio activity, and a €1 billion senior unsecured notes offering. See our latest analysis for W. P. Carey. The recent earnings beat, higher 2026 AFFO guidance and the €1b senior unsecured notes offering appear to sit behind a clear shift in sentiment, with a 10.95% 3 month share price return and a 33.76% 1 year total shareholder return...
NasdaqGS:HTHT
NasdaqGS:HTHTHospitality

Assessing H World Group (NasdaqGS:HTHT) Valuation After Launch Of Budget-Focused Hanting Inn Brand

H World Group (HTHT) has launched Hanting Inn, a new economy hotel brand aimed at lower tier cities and price sensitive markets, using a low investment, asset light model tailored for faster expansion. See our latest analysis for H World Group. H World Group’s new Hanting Inn launch comes as the share price sits at US$52.53, with a 30 day share price return of 7.12% and a 90 day share price return of 16.17%. The 1 year total shareholder return of 51.79% suggests momentum has been building...
NYSE:CACI
NYSE:CACIProfessional Services

Insider Sales At CACI International Contrast With Bullish Analyst Outlook

CACI International Executive Vice President and General Counsel, William Koegel, sold 2,000 shares of NYSE:CACI. This was his latest transaction in a pattern of insider selling over the past year, with no insider purchases reported in that period. The activity comes with CACI International shares recently closing at $573.3. For investors watching NYSE:CACI, this cluster of insider sales is arriving after a strong longer term share move, with the stock up 69.4% over the past year and 144.7%...
NYSE:MRK
NYSE:MRKPharmaceuticals

Is Merck’s First PD-1 Ovarian Cancer Approval Reshaping The Investment Case For Merck (MRK)?

In early February 2026, Merck received FDA approval for KEYTRUDA and KEYTRUDA QLEX plus paclitaxel, with or without bevacizumab, for adults with PD-L1 positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma after one or two prior systemic treatments. This marks the first approval of a PD-1 inhibitor regimen for this hard-to-treat setting, broadening KEYTRUDA’s reach in women’s cancers and reinforcing Merck’s oncology franchise. Next, we’ll examine how...
NYSE:NEU
NYSE:NEUChemicals

Assessing NewMarket (NEU) Valuation As Shares Trade Near Half Of DCF Fair Value Estimate

What recent returns say about NewMarket With no single headline event setting the tone, NewMarket (NEU) has been moving under the radar. The stock has shown a 0.7% decline over the past day and weaker performance over the past week. See our latest analysis for NewMarket. Beyond the latest 0.7% daily share price decline, NewMarket’s recent 7 day and 90 day share price returns of 17.0% and 21.1% point to fading short term momentum. At the same time, 1 year and 3 year total shareholder returns...
NYSE:TWO
NYSE:TWOMortgage REITs

Two Harbors Investment (TWO) Is Up 5.8% After Swinging From 2025 Profit To Loss - Has The Bull Case Changed?

Two Harbors Investment Corp. recently reported fourth-quarter 2025 results, with net income falling to US$11.72 million and a basic loss per share from continuing operations of US$0.02, compared with basic earnings per share of US$2.54 a year earlier. For the full year 2025, the company moved from net income of US$298.17 million to a net loss of US$454.30 million, underscoring a sharp swing in profitability that reframes how investors may view its risk and return profile. Against this...
NasdaqGM:VITL
NasdaqGM:VITLFood

Vital Farms (VITL) Is Up 8.8% After Strong Revenue Beat And Ahead Of 2025 Results - What's Changed

Vital Farms recently reported quarterly results showing a 37.2% year-over-year revenue increase and an earnings per share beat, while also preparing to release its fourth-quarter and full-year 2025 results on February 26, 2026. At the same time, the company’s valuation is graded favorably versus peers even as consensus earnings estimates have softened slightly, creating a nuanced picture for investors. Next, we’ll examine how Vital Farms’ combination of strong recent revenue growth and a...
NYSE:STAG
NYSE:STAGIndustrial REITs

Stronger Q4 Results And Higher Dividend Might Change The Case For Investing In STAG Industrial (STAG)

STAG Industrial, Inc. reported past full-year 2025 results showing sales of US$843.01 million, revenue of US$845.18 million, and net income of US$273.52 million, alongside strong Q4 leasing activity, high occupancy of 96.4%, and meaningful property acquisitions. The company’s 6.3% increase in core FFO per share, 4% dividend raise, the largest since 2014, and shift to quarterly payments underscore how heightened leasing, acquisitions, and disciplined balance sheet management are reshaping its...
NYSE:KFY
NYSE:KFYProfessional Services

A Look At Korn Ferry (KFY) Valuation As Quality Metrics Clash With Cost And Market Pressures

Recent analysis of Korn Ferry (KFY) has drawn attention to its strong return on invested capital and profit quality, while also flagging end market pressures and rising expenses that are shaping a more cautious investor mood. See our latest analysis for Korn Ferry. The recent 7 day share price return of 8.09% decline and 30 day share price return of 9.92% decline, alongside a relatively modest 5.90% decline in 1 year total shareholder return and positive 3 and 5 year total shareholder...
NasdaqGS:TW
NasdaqGS:TWCapital Markets

Did Tradeweb’s MAXEX Push and Bigger Buyback Just Shift Tradeweb Markets' (TW) Investment Narrative?

In February 2026, Tradeweb Markets Inc. reported fourth-quarter 2025 revenue of US$521.18 million and net income of US$324.99 million, raised its quarterly dividend to US$0.14 per share, completed a prior share repurchase program, authorized a new US$500 million buyback, and earlier this month announced a commercial collaboration and investment with MAXEX to link its more than 3,000 global clients to MAXEX’s roughly 400 U.S. mortgage lenders and institutional investors. By connecting...
NasdaqGS:FOXA
NasdaqGS:FOXAMedia

Fox Taps Disney Veteran Aragón To Refresh Advertising And Investor Story

Fox (NasdaqGS:FOXA) has appointed Lucas P. Aragón as Senior Vice President, Creative at FOX Advertising. Aragón joins from Disney, bringing experience across major networks including OWN. The hire signals a focus on creative branding and client facing campaigns within Fox's advertising business. For investors tracking Fox at a current share price of $56.35, this leadership move arrives after a mixed return profile, with a 2.3% gain over the past year alongside a 58.4% return over three...